Codexis details plans for $100M IPO

Codexis has joined the year-end rush to file an IPO. The biotech company, which produces enzymes, microbes and other industrial catalysts for drugmakers and companies in the energy and environmental fields, plans to raise $100 million through its initial public offering. Some of that money could be used to buy up new technologies, as well as increase the company's production capacity. In the first nine months of this year, Codexis saw its revenue swell by 84 percent.

The Redwood City, CA-based biotech's clients include Dr. Reddy's Laboratories, Merck, Pfizer and Ranbaxy Laboratories.  No date has been set for the IPO, and Codexis didn't spell out how many shares it plans to sell. Shares will trade on Nasdaq under CDXS.

- check out the Codexis release
- read the story from Dow Jones
- here's the AP report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.